Jagsonpal Pharmaceuticals
NSE: JAGSNPHARM · ISIN INE048B01035 · Healthcare
₹217.36−0.03 (−0.01%)
Monday 9 November, 12:45 IST. Delayed. Source: Yahoo Finance.
Price chart
₹217.36 −0.03 (−0.01%) today
The day
- Previous close
- ₹217.39
- Open
- ₹217.39
- Day high
- ₹219.08
- Day low
- ₹216.03
Listed on NSE since 1 March 2000.
Key numbers
- Market value
- ₹1,436.06 Cr
- P/E (trailing)
- 32.59
- EPS (trailing)
- ₹6.67
- Price to book
- 5.97
- Dividend yield
- 1.17%
- Return on equity
- 18.2%
- Debt to equity
- 0.04
- Profit margin
- 14.3%
- Beta
- -0.26
- Volume today
- 10,296
- Average volume
- 2.50 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹236.71 Cr | ₹26.72 Cr |
| FY24 | ₹208.70 Cr | ₹22.46 Cr |
| FY25 | ₹268.72 Cr | ₹55.36 Cr |
| FY26 | ₹287.23 Cr | ₹43.08 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹96 Cr | ₹12 Cr | – |
Source: Jagsonpal Pharmaceuticals’s results filed with NSE, consolidated (the whole group). Net profit is the share of Jagsonpal Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 |
|---|---|
| Fixed assets | ₹58.60 L |
| Inventories | ₹27 Cr |
| Owed by customers | ₹37 Cr |
| Cash and equivalents | ₹19 Cr |
| Total assets | ₹318 Cr |
| Borrowings | ₹89.60 L |
| Total liabilities | ₹74 Cr |
| Shareholders’ equity | ₹241 Cr |
Source: Jagsonpal Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Jagsonpal Pharmaceuticals
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Gurugram
- Employees
- 1,297
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Jagsonpal Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 4 Per Share
Dividend · ex-date 4 September 2026
- Buy Back
Buyback · ex-date 4 May 2026
- Dividend - Rs 2.50 Per Share
Dividend · ex-date 12 September 2025
- Face Value Split (Sub-Division) - From Rs 5/- Per Share To Rs 2/- Per Share
Split · ex-date 8 January 2025
- Dividend - Rs 5 Per Share
Dividend · ex-date 6 September 2024
- Dividend - Rs 5 Per Share
Dividend · ex-date 21 August 2023
- Extra Ordinary General Meeting
Action · ex-date 8 June 2022
- Interim Dividend - Rs 4 Per Share
Dividend · ex-date 29 October 2021 · record date 1 November 2021
Source: NSE. Latest first, 8 of 20.
Information only, not investment advice. Prices are delayed.